Results for this period
First quarter1 January 2026–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Sales of “Gla-Alpha Combination Ophthalmic Solution” performed well in Japan and Asia, but royalties from “TissueBlue™” were not included in first-quarter revenue because discussions regarding the contract extension are ongoing. Research and development expenses decreased due to lower development costs, while other selling, general and administrative expenses decreased mainly because of lower personnel expenses.
A description of significant events is included. However, there are no applicable notes regarding the going concern assumption, and the company recognizes that there are no material uncertainties.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | ¥15 million (YoY -84.4%) |
| Operating profit | ¥-167 million |
| Ordinary income | ¥-170 million |
| Profit attributable to owners of the parent | ¥-170 million |
| Net income per share | △¥3.14 |
| Equity ratio | End of the current fiscal period 66.7 / End of previous period 66.1 |
| Total assets | ¥1,968 million |
| Net assets | ¥1,314 million |
| Full-year earnings forecast | Net Sales ¥300 million (YoY -22.6%) / Operating profit ¥-780 million / Ordinary income ¥-800 million / Net income ¥-800 million |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Depreciation and amortization | ¥1,148 thousand |
| Disclosure regarding the going concern assumption | A description of significant events is included. However, there are no applicable notes regarding the going concern assumption, and the company recognizes that there are no material uncertainties. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | None (the number and names of companies newly consolidated or excluded are not disclosed) |
| Material subsequent events | On 10 April 2026, payment was completed for 2,150,500 new shares issued through a third-party allotment to Senju Pharmaceutical Co., Ltd., raising estimated net proceeds of ¥194,996,500. On 14 May 2026, payment was completed for the issuance of 501,200 restricted shares. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 54,831,712 shares |
| Treasury Shares at Period-End | 11,386 shares |
| Factors Behind Changes in Business Performance | Sales of “Gla-Alpha Combination Ophthalmic Solution” performed well in Japan and Asia, but royalties from “TissueBlue™” were not included in first-quarter revenue because discussions regarding the contract extension are ongoing. Research and development expenses decreased due to lower development costs, while other selling, general and administrative expenses decreased mainly because of lower personnel expenses. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Royalties from “TissueBlue™” were not included in first-quarter revenue because the details of the contract extension are still under discussion, and are expected to be recognized together after the contract is extended. Meanwhile, research and development expenses decreased due to lower development costs for “H-1337” and “DWR-2206,” while other selling, general and administrative expenses decreased mainly because of lower personnel expenses.